In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CardioNet heads for potential $150m IPO (initial public offering):

This article was originally published in Clinica

Executive Summary

Heart monitor developer CardioNet has filed for an initial public offering which the company claims could have a maximum price offering approaching $150m. The San Diego, California-based firm did not disclose the expected number of shares to be offered but did state that it would use the proceeds to pay an outstanding term loan and a success fee connected to the IPO to Silicon Valley Bank. Funds will also be channelled towards increasing sales and marketing capabilities for the company's CardioNet System, which monitors and diagnoses heart rhythm disorders. Over the last three years, the company has cut its net loss considerably, posting a deficit of $6.7m in 2006, down 68% from a loss of $21m in 2004. CardioNet plans to list on the Nasdaq under the ticker symbol "BEAT".

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT049533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel